LENZ Therapeutics, Inc. Cash Flow Statement
LENZ / Health Care|6 years of annual SEC 10-K data (FY2020-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 6 fiscal years. All figures from audited SEC 10-K filings.
LENZ Therapeutics, Inc. used $69M in operating cash flow and negative free cash flow of $70M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.71 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Income | -$82.1M | -$49.8M | -$70.0M | -$101.1M | -$70.8M | -$68.4M |
| Depreciation & Amortization | $287.0K | $58.0K | $15.0K | $2.4M | $734.0K | $121.0K |
| Operating Cash Flow | -$69.2M | -$59.4M | -$60.4M | -$88.0M | -$52.9M | -$8.7M |
| Capital Expenditures | $827.0K | $468.0K | $30.0K | $6.6M | $5.7M | $1.5M |
| Free Cash Flow | -$70.0M | -$59.9M | -$60.4M | -$94.6M | -$58.6M | -$10.3M |
| FCF Margin | -366.7% | - | - | - | - | - |